We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$483M
AUM Growth
-$111M
Cap. Flow
-$58.5M
Cap. Flow %
-12.12%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$17.6M
2
STAA icon
STAAR Surgical
STAA
+$12M
3
IMDX
Insight Molecular Diagnostics
IMDX
+$4.84M
4
IMPR
IMPRIVATA, INC COM
IMPR
+$792K

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$82.9M
2
LCTX icon
Lineage Cell Therapeutics
LCTX
+$3.92M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.19%
2 Healthcare 35.87%
3 Technology 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNST icon
1
Monster Beverage
MNST
$94.3B
$213M 44.19%
9,594,816
– –
STAA icon
2
STAAR Surgical
STAA
$1.21B
$77M 15.95%
10,417,670
+1,770,747
+20% +$12M
LCTX icon
3
Lineage Cell Therapeutics
LCTX
$269M
$63.6M 13.18%
25,333,905
-1,756,344
-6% -$3.92M
IWM icon
4
iShares Russell 2000 ETF
IWM
$79.8B
$46.5M 9.63%
420,000
+170,000
+68% +$17.6M
CYNO
5
DELISTED
Cynosure, Inc. Class A
CYNO
$40.5M 8.38%
916,975
– –
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$19.8M 4.09%
322,411
-1,297,557
-80% -$82.9M
IMPR
7
DELISTED
IMPRIVATA, INC COM
IMPR
$9.32M 1.93%
737,911
+69,385
+10% +$792K
AST
8
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$7.71M 1.6%
1,641,025
– –
IMDX
9
Insight Molecular Diagnostics
IMDX
$150M
$5.04M 1.04%
+54,661
New +$4.84M

Similar funds

PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.41B AUM 18.71% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return

Broadwood Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Broadwood Capital held 10 positions worth $483M, down 19% from $594M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital withdrew a net $58.5M in Q1 2016, closing 1 position and reducing 2 holdings. Its largest reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $82.9M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 40% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Broadwood Capital opened a new position in Insight Molecular Diagnostics worth $5.04M.

  • Broadwood Capital's largest Q1 2016 buy was Insight Molecular Diagnostics: 54,661 shares worth $5.04M.
  • Broadwood Capital added most to iShares Russell 2000 ETF in Q1 2016, an estimated $17.6M increase.
  • Broadwood Capital's biggest Q1 2016 reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $82.9M.
  • Broadwood Capital's ten largest holdings make up 100% of its $483M portfolio in Q1 2016.
  • Broadwood Capital opened 1 new position and closed 1 in Q1 2016.
  • Broadwood Capital's portfolio value fell 19% quarter-over-quarter to $483M.

Based on Broadwood Capital's 13F filing for Q1 2016, filed 16 May 2016.